Vascular News and Research

RSS

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

InfraReDx to display Lipiscan at TCT scientific meeting

InfraReDx today announced its preliminary schedule of events at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from Monday, September 21st to Friday, September 25th, in San Francisco, CA. at the Moscone Center.

14 Sep 2009

Wisconsin researchers identify the genetic region responsible for cardiovascular collapse during anesthesia

Researchers at The Medical College of Wisconsin in Milwaukee have identified the genetic region in rats responsible for cardiovascular collapse during anesthesia. While it is well known that people have different cardiovascular sensitivity to anesthesia causing some to collapse even when low doses are administered, the mechanism responsible for this susceptibility is not clear.

11 Sep 2009

Newly established Edward Neurosciences Institute to provide advanced stroke care in Chicago

Edward Hospital announced today that it has established the Edward Neurosciences Institute in affiliation with the Northwestern Medical Faculty Foundation to bring the highest level of stroke care in the world to the west and southwest suburbs of Chicago.

11 Sep 2009

ThromboGenics shortlisted for two awards at the Scrip Awards 2009

ThromboGenics NV, a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009.

11 Sep 2009

Abbott to acquire Evalve for $410 million

Abbott announced today a definitive agreement to acquire the outstanding equity of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of cardiac mitral valves.

10 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Board-certified vascular surgeon joins VIVA

Virginia Interventional and Vascular Associates (VIVA) and its parent group, Radiologic Associates of Fredericksburg (RAF) Ltd., announce that Victor J. D'Addio, M.D., FACS, has joined the practice. Dr. D'Addio is a board-certified vascular surgeon. Together, the practice offers streamlined services for vascular patients and referring physicians -- from office-based vascular testing to minimally invasive treatments and traditional surgery.

10 Sep 2009

Free, online self-assessment quiz helps assess health and lifestyle risks for PAD

As recent medical studies continue to highlight the seriousness of peripheral arterial disease (or PAD) and its association with heart attack, stroke and early mortality, the Society of Interventional Radiology Foundation recommends that older Americans, smokers and diabetics take its free, online self-assessment quiz.

10 Sep 2009

Society of Interventional Radiology's resources emphasize on PAD

The Society of Interventional Radiology offers numerous resources just in time for September's national peripheral arterial disease (or PAD) awareness month. As recent medical studies continue to highlight the seriousness of PAD, these resources are welcome additions to libraries for interventional radiologists and primary care physicians who want to learn more about minimally invasive treatments for this disease that affects an estimated 10 million people in the United States.

10 Sep 2009

New findings may help identify treatments for diabetes and hyperinsulinemia

By investigating a rare and severe form of diabetes in children, University of Iowa researchers have discovered a new molecular mechanism that regulates specialized pancreatic cells and insulin secretion. The mechanism involves a protein called ankyrin, which UI researchers previously linked to potentially fatal human heart arrhythmias.

9 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

Exposure to air pollution can cause heart attack

It's well known that measures such as exercise, a healthy diet and not smoking can help reduce high blood pressure, but researchers at the University of Michigan Health System have determined the very air we breathe can be an invisible catalyst to heart disease.

8 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

Harmless shard from childhood virus shell may halt biological process

A harmless shard from the shell of a common childhood virus may halt a biological process that kills a significant percentage of battlefield casualties, heart attack victims and oxygen-deprived newborns, according to research presented Sunday, September 6, 2009, at the 12th European meeting on complement in human disease in Budapest, Hungary.

7 Sep 2009

Angiotensin II receptors not detectable in pregnant or preeclamptic women

A new study by researchers at Wake Forest University School of Medicine reveals a key component in the development of preeclampsia in pregnant women, a condition that can result in miscarriage and maternal death.

5 Sep 2009

Winner of 2009 Gerald A. Beathard Fellowship award announced

Lifeline Vascular Access(SM), the nation's leading provider of vascular access management services, today announced that Dr. Stephen Osaguona has been awarded the 2009 Gerald A. Beathard Fellowship in Interventional Nephrology.

5 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Medipattern raises funds for general working capital purposes

The Medipattern Corporation ("Medipattern" or the "Company") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 2,500,000 common shares in the capital stock of the Company at $0.20 per common share, for gross proceeds of $500,000.00 to the Company.

3 Sep 2009